ATE170839T1 - Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheiten - Google Patents
Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheitenInfo
- Publication number
- ATE170839T1 ATE170839T1 AT95910164T AT95910164T ATE170839T1 AT E170839 T1 ATE170839 T1 AT E170839T1 AT 95910164 T AT95910164 T AT 95910164T AT 95910164 T AT95910164 T AT 95910164T AT E170839 T1 ATE170839 T1 AT E170839T1
- Authority
- AT
- Austria
- Prior art keywords
- indole derivatives
- estrogen
- treatment
- neoplasms
- diseases
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 229940054051 antipsychotic indole derivative Drugs 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 150000002475 indoles Chemical class 0.000 abstract 2
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
- C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20005794A | 1994-02-22 | 1994-02-22 | |
| US36204694A | 1994-12-22 | 1994-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE170839T1 true ATE170839T1 (de) | 1998-09-15 |
Family
ID=26895427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95910164T ATE170839T1 (de) | 1994-02-22 | 1995-01-31 | Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheiten |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5877202A (de) |
| EP (1) | EP0746544B1 (de) |
| JP (1) | JP3536258B2 (de) |
| KR (1) | KR100362864B1 (de) |
| CN (1) | CN1141627A (de) |
| AT (1) | ATE170839T1 (de) |
| AU (1) | AU680740B2 (de) |
| CA (1) | CA2183731C (de) |
| DE (1) | DE69504637T2 (de) |
| DK (1) | DK0746544T3 (de) |
| ES (1) | ES2122555T3 (de) |
| FI (1) | FI963272L (de) |
| HU (1) | HUT76133A (de) |
| IL (1) | IL112700A0 (de) |
| NO (1) | NO963483L (de) |
| NZ (1) | NZ281431A (de) |
| WO (1) | WO1995022524A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW397821B (en) * | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
| US5880137A (en) * | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| US6200760B1 (en) * | 1997-02-24 | 2001-03-13 | Cornell Research Foundation, Inc. | Method of screening agents as candidates for drugs or sources of drugs |
| US6150395A (en) | 1997-05-30 | 2000-11-21 | The Regents Of The University Of California | Indole-3-carbinol (I3C) derivatives and methods |
| US6069153A (en) * | 1998-05-12 | 2000-05-30 | American Home Products Corporation | Indenoindoles and benzocarbazoles as estrogenic agents |
| US6479535B1 (en) | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| CN1309637A (zh) * | 1998-05-15 | 2001-08-22 | 美国家用产品公司 | 包含2－苯基－吲哚化合物和雌激素制剂的组合物 |
| US6207700B1 (en) * | 1999-01-07 | 2001-03-27 | Vanderbilt University | Amide derivatives for antiangiogenic and/or antitumorigenic use |
| US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
| PL354179A1 (en) * | 1999-09-13 | 2003-12-29 | Wyethwyeth | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols |
| DE19962300A1 (de) * | 1999-12-23 | 2001-06-28 | Asta Medica Ag | Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung |
| EP1254115A2 (de) * | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Cannabinoid-rezeptor modulatoren, verfahren zu ihrer herstellung, und verwendung der cannabinoid-rezeptor modulatoren um respiratorische und nicht respiratorische krankheiten zu behandeln |
| US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| US6326501B1 (en) * | 2000-04-19 | 2001-12-04 | Hoffmann-La Roche Inc. | Methylation of indole compounds using dimethyl carbonate |
| CA2424222A1 (en) * | 2000-10-02 | 2002-04-11 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US20030130199A1 (en) * | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
| FR2842526B1 (fr) | 2002-07-16 | 2007-07-13 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments |
| CN1791402A (zh) * | 2003-03-27 | 2006-06-21 | 麦克公司 | 治疗眼高压的眼科组合物 |
| US7491744B2 (en) | 2004-04-26 | 2009-02-17 | Vanderbilt University | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity |
| US8765488B2 (en) | 2004-07-22 | 2014-07-01 | The Board Of Trustees Of The University Of Illinois | Sensors employing single-walled carbon nanotubes |
| JP5460054B2 (ja) | 2005-11-23 | 2014-04-02 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法 |
| EP2488025A4 (de) | 2009-10-15 | 2013-04-03 | Childrens Medical Center | Sepiapterinreduktasehemmer für schmerzbehandlung |
| JP2013538060A (ja) | 2010-08-30 | 2013-10-10 | アルゼダ コーポレーション | レブリン酸、レブリン酸エステル、バレロラクトン、およびこれらの誘導体の産生のための発酵経路 |
| EP3078374B1 (de) | 2011-10-17 | 2019-06-19 | Vanderbilt University | Indomethacin-analoga zur behandlung von kastrationsresistentem prostatakrebs |
| EP2800738B1 (de) | 2012-01-06 | 2020-04-08 | Novartis AG | Heterocyclische verbindungen und verfahren zu ihrer verwendung |
| JP5997288B2 (ja) * | 2012-03-05 | 2016-09-28 | 大連理工大学 | ナフタレンを基本骨格とする二光子蛍光プローブ、その製造方法及びその利用方法 |
| TWI747873B (zh) | 2016-02-01 | 2021-12-01 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
| WO2018125992A1 (en) * | 2016-12-28 | 2018-07-05 | Promega Corporation | Functionalized nanoluc inhibitors |
| WO2022232931A1 (en) * | 2021-05-05 | 2022-11-10 | Kare Chemical Technologies Inc. | Catalytic tryptamine processes and precursors |
| CN116410120A (zh) * | 2023-04-19 | 2023-07-11 | 四川农业大学 | 一种2-苯基吲哚酰胺类抗肿瘤化合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1482845A (fr) * | 1964-12-31 | 1967-06-02 | Merck & Co Inc | Composés de l'indol |
| ATE118207T1 (de) * | 1989-12-04 | 1995-02-15 | Searle & Co | Heterozyklische acylaminodiol-beta-aminosäure- derivate. |
| AU650261B2 (en) * | 1990-03-07 | 1994-06-16 | Rhone-Poulenc Rorer S.A. | Derivatives of glycinamide, their preparation and medicaments containing them |
| US5312928A (en) * | 1991-02-11 | 1994-05-17 | Cambridge Neuroscience | Calcium channel antagonists and methodology for their identification |
| AU665690B2 (en) * | 1992-05-08 | 1996-01-11 | Otsuka Pharmaceutical Factory, Inc. | Indole derivative |
| JPH0835029A (ja) * | 1994-07-19 | 1996-02-06 | Toyota Motor Corp | 高強度高延性鋳造アルミニウム合金およびその製造方法 |
-
1995
- 1995-01-31 ES ES95910164T patent/ES2122555T3/es not_active Expired - Lifetime
- 1995-01-31 NZ NZ281431A patent/NZ281431A/en unknown
- 1995-01-31 WO PCT/US1995/001372 patent/WO1995022524A1/en active IP Right Grant
- 1995-01-31 EP EP95910164A patent/EP0746544B1/de not_active Expired - Lifetime
- 1995-01-31 CA CA002183731A patent/CA2183731C/en not_active Expired - Lifetime
- 1995-01-31 DE DE69504637T patent/DE69504637T2/de not_active Expired - Lifetime
- 1995-01-31 KR KR1019960704579A patent/KR100362864B1/ko not_active Expired - Fee Related
- 1995-01-31 HU HU9602299A patent/HUT76133A/hu unknown
- 1995-01-31 DK DK95910164T patent/DK0746544T3/da active
- 1995-01-31 AT AT95910164T patent/ATE170839T1/de not_active IP Right Cessation
- 1995-01-31 JP JP52182295A patent/JP3536258B2/ja not_active Expired - Lifetime
- 1995-01-31 CN CN95191750A patent/CN1141627A/zh active Pending
- 1995-01-31 AU AU18373/95A patent/AU680740B2/en not_active Ceased
- 1995-02-20 IL IL11270095A patent/IL112700A0/xx unknown
-
1996
- 1996-01-31 US US08/594,505 patent/US5877202A/en not_active Expired - Lifetime
- 1996-08-21 FI FI963272A patent/FI963272L/fi unknown
- 1996-08-21 NO NO963483A patent/NO963483L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU680740B2 (en) | 1997-08-07 |
| EP0746544A1 (de) | 1996-12-11 |
| JPH09509169A (ja) | 1997-09-16 |
| FI963272A0 (fi) | 1996-08-21 |
| FI963272L (fi) | 1996-08-21 |
| DE69504637T2 (de) | 1999-05-06 |
| DK0746544T3 (da) | 1999-06-07 |
| ES2122555T3 (es) | 1998-12-16 |
| WO1995022524A1 (en) | 1995-08-24 |
| KR100362864B1 (ko) | 2003-04-16 |
| HUT76133A (en) | 1997-06-30 |
| NO963483L (no) | 1996-10-22 |
| IL112700A0 (en) | 1995-05-26 |
| NZ281431A (en) | 1997-09-22 |
| US5877202A (en) | 1999-03-02 |
| CA2183731C (en) | 2000-03-21 |
| AU1837395A (en) | 1995-09-04 |
| HU9602299D0 (en) | 1996-10-28 |
| EP0746544B1 (de) | 1998-09-09 |
| CN1141627A (zh) | 1997-01-29 |
| JP3536258B2 (ja) | 2004-06-07 |
| CA2183731A1 (en) | 1995-08-24 |
| DE69504637D1 (de) | 1998-10-15 |
| NO963483D0 (no) | 1996-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69504637D1 (de) | Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheiten | |
| DE69521620D1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
| ATE230757T1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
| ATE224189T1 (de) | Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit | |
| DE60236413D1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
| ATE282413T1 (de) | Verwendung von tempol zur behandlung von essentiellem hochdruck | |
| DE69839815D1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
| ATE230417T1 (de) | Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien | |
| DE69831406D1 (de) | Verwendung von thiazolidinedion-derivaten zur behandlung des polyzystischen ovarien syndroms und des schwangerschaftsdiabetes | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| TNSN99145A1 (fr) | Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate | |
| DE69830728D1 (de) | Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz | |
| ATE221781T1 (de) | Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms | |
| DE69526937D1 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
| DE69725879D1 (de) | VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN | |
| DE69413829D1 (de) | Antiglucocorticoidsteroide zur behandlung von angststörungen | |
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| ATE201992T1 (de) | Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen | |
| ATE210447T1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| ATE293994T1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
| DE60006519D1 (de) | Glutathion-reduktase zur behandlung und prophylaxe von aids | |
| NO980375L (no) | Humant MP52 Arg protein | |
| DE60000937D1 (de) | Verwendung von 15-deoxyspergualin zur behandlung von hyperreaktiven entzündlichen erkrankungen und autoimmunerkrankungen | |
| RU94000387A (ru) | Способ лечения врожденного вывиха надколенника |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |